Sign in

You're signed outSign in or to get full access.

Christopher Green

Vice President & Chief Technology Officer at ScanTech AI Systems
Executive

About Christopher Green

Dr. Christopher Green (age 47) is Vice President & Chief Technology Officer at ScanTech AI Systems Inc. (STAI) since the January 2025 business combination, having previously served as Vice President – Engineering at ScanTech Identification Beam Systems, LLC since June 1, 2016; his background spans computer‑aided engineering design and lab experimentation, with lead responsibility for developing and optimizing proprietary threat‑detection algorithms for CT checkpoint scanners . Education: B.S. Mathematics (Morehouse College); B.S., M.S., and Ph.D. in Mechanical Engineering (Georgia Institute of Technology) . The company has not disclosed TSR, revenue growth, or EBITDA growth metrics tied to his individual performance or compensation .

Past Roles

OrganizationRoleYearsStrategic Impact
ScanTech Identification Beam Systems, LLC (SIBS)Vice President – Engineering2016–2024Led algorithm development and engineering for next‑generation low‑energy checkpoint scanners; optimization of proprietary threat‑detection algorithms .
ScanTech Identification Beam Systems, LLC (SIBS)Senior Program EngineerNot disclosedProvided technical/programmatic leadership in design, fabrication, and development of checkpoint scanners prior to promotion .

Fixed Compensation

Metric (USD)FY 2022FY 2023FY 2024
Base Salary$267,000 $267,000 $305,000
Target Bonus %Not disclosed
Actual Bonus Paid$137,000
Equity Awards (Grant‑date FV)$300,000
Total Reported Compensation$267,000 $267,000 $742,000

Performance Compensation

Incentive TypeMetricWeightingTargetActualPayout ($)Vesting
Annual Cash Bonus (FY 2024)Not disclosed Not disclosed Not disclosed Not disclosed $137,000 Cash bonus for FY 2024; vesting terms not disclosed .
Equity Award (FY 2024)Not disclosed (RSU/PSU/option form not specified) Not disclosed Not disclosed Not disclosed $300,000 grant‑date fair value Individual vesting schedule not disclosed; plan allows time‑based RSUs and performance awards .

The 2025 Equity Incentive Plan permits options, RSUs, and performance awards; prohibits option repricing without shareholder approval; and provides for administrative discretion on vesting and performance criteria, but specific performance metrics/weightings for Dr. Green are not disclosed .

Equity Ownership & Alignment

ItemValueNotes
Common shares beneficially owned135,214 shares Listed under “Directors and Named Executive Officers.”
Ownership as % of shares outstanding<1.0% Company had 71,219,522 shares outstanding at record date .
RSUs/Options vesting within 60 days (record date)Not disclosed for Dr. Green Proxy footnotes show 60‑day RSUs for certain directors; no such footnote for Dr. Green .
Exercisable vs. unexercisable optionsNot disclosed; no outstanding equity awards at 12/31/2024 FY 2024 table shows none outstanding for Dr. Green .
Shares pledged as collateralProhibited by company policy Anti‑hedging/pledging policy applies to directors and officers .
Stock ownership guidelinesNot disclosed Corporate Governance Principles disclosed, but no specific executive ownership multiples .

Employment Terms

TermDetails
Employment start & progressionSIBS employment agreement dated June 1, 2014 (Director of Engineering); later promoted to Vice President – Engineering; serves as VP & CTO of STAI since the January 2025 business combination .
Base salary (historical)$178,700 originally; subsequently increased to $267,000 under the SIBS agreement; public‑company salary in 2024 reported at $305,000 .
SeveranceIf terminated without Cause or for Good Reason under the SIBS “Green Agreement,” entitled to one year of base salary .
Change‑of‑Control treatment (plan‑level)Upon “change in control,” options become immediately exercisable; RSUs/restricted stock become fully vested/non‑forfeitable; performance award conditions lapse (plan‑wide terms) .
ClawbackCompany adopted clawback policy in line with SEC/Nasdaq rules; recovery of erroneously awarded incentive compensation for restatements over prior three fiscal years .
Hedging/PledgingHedging/monetization transactions and pledging of company securities are prohibited for certain officers/directors .
Non‑compete / Non‑solicitNot disclosed in proxy/10‑K excerpts .
Contract term/auto‑renewalNot disclosed .

Investment Implications

  • Pay mix has evolved to a public‑company framework with material equity participation (FY 2024: $300,000 equity FV and $137,000 cash bonus), increasing alignment but with limited transparency on underlying performance metrics, which weakens pay‑for‑performance evaluation .
  • Plan‑level single‑trigger change‑of‑control acceleration for all outstanding equity (options/RSUs/performance awards) can heighten retention risk around strategic transactions and may front‑load value realization irrespective of post‑deal performance; monitor any M&A processes and potential award overhang .
  • Ownership is modest (<1%) and pledging/hedging is prohibited—reducing misalignment risks tied to collateralization or derivative hedging—but low absolute ownership suggests moderate “skin‑in‑the‑game”; further RSU grants under the 2025 Plan could strengthen alignment over time .
  • The 2025 Plan amendments (6.8M share increase and 3% evergreen for up to 9 additional years) expand long‑term equity capacity, supporting talent retention but also increasing dilution potential; assess burn rate (9% in 2025) and cumulative overhang when benchmarking executive awards .
  • Company‑level capital structure actions (reverse split authorization to address Nasdaq bid‑price deficiency) may affect realized value of equity awards and could influence timing of insider liquidity; track board actions on split ratio and subsequent listing compliance .